Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020; it does not identify Bio Green Med Solution, Inc. as the registrant. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its pipeline includes fadraciclib, sapacitabine, seliciclib and CYC140, all being evaluated in Phase 1 studies.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The company reported no revenue in either comparative period; management said there were no active collaboration, licensing or clinical supply agreements and expected no revenue for the foreseeable future.
| Metric | Three months ended June 30, 2019 | Three months ended June 30, 2020 | Six months ended June 30, 2019 | Six months ended June 30, 2020 |
|---|---|---|---|---|
| Research and development expense | $1.153 | $1.163 | $2.165 | $2.270 |
| General and administrative expense | $1.184 | $1.309 | $2.376 | $2.626 |
| Total operating expenses | $2.337 | $2.472 | $4.541 | $4.896 |
| Operating loss | $(2.337) | $(2.472) | $(4.541) | $(4.896) |
| Net loss | $(1.783) | $(2.166) | $(3.625) | $(3.386) |
| Net loss applicable to common shareholders | $(1.833) | $(2.216) | $(3.726) | $(3.487) |
| Basic and diluted loss per share | $(2.13) | $(0.58) | $(4.83) | $(1.48) |
Gross and operating margins are not meaningful because the company had no revenue. Six-month 2020 other income included $835,000 from royalties under a legacy asset purchase agreement; the amount and timing of future royalty income are uncertain. The company also recorded a $576,000 income tax benefit, primarily related to U.K. research and development tax credits.
At June 30, 2020, cash and cash equivalents were $25.342 million, total current assets $27.933 million, current liabilities $1.512 million and working capital $26.421 million. Total liabilities were $2.593 million, including a $1.081 million lease liability; the filing reports no other liabilities and describes no reliance on institutional credit financing. Stockholders’ equity was $26.578 million and accumulated deficit was $361.013 million.
For the six months ended June 30, 2020, operating cash outflow was $4.653 million, investing cash outflow $4,000 and financing cash inflow $18.206 million. Cash increased by $13.457 million from year-end 2019. Management said June 30 cash was expected to fund operating expenses and capital requirements through the end of 2022, but not to complete development and commercialization of any drug candidate.
Material changes versus the prior comparable period
- Second-quarter operating expenses rose $135,000 year over year, while net loss widened by $383,000. For the first half, operating expenses increased $355,000, but net loss improved by $239,000, largely reflecting higher other income.
- First-half research and development spending increased $105,000: transcriptional regulation spending rose $426,000 as fadraciclib development progressed, partly offset by lower spending on sapacitabine, CYC140 and other programs.
- First-half general and administrative expenses increased $250,000, primarily from legal and professional costs.
- First-half other income rose to $934,000 from $341,000, principally due to the $835,000 legacy royalty recognition. Conversely, second-quarter other income fell to $20,000 from $247,000.
- Cash increased substantially following an April 2020 equity financing. The company issued common shares, pre-funded warrants and accompanying warrants and received approximately $18.4 million net proceeds. All 2.09 million pre-funded warrants were converted to common shares during the quarter. The 4.0 million accompanying warrants were exercisable at $5 per share for five years; 3.996 million remained outstanding at June 30.
- A one-for-twenty reverse stock split was completed April 14, 2020. Common shares outstanding were 4,863,984 as of August 12, 2020, versus 859,998 at December 31, 2019; reported share and per-share data were retrospectively adjusted for the split.
Outlook, risks and unusual items
Management expected 2020 research and development expense to increase as clinical programs advanced, and general and administrative expense to increase slightly, primarily because of legal and professional costs. The company expects continued operating losses and may need additional capital beyond its stated runway. If financing is unavailable on acceptable terms, it may delay, reduce or discontinue trials or research programs, or seek earlier-stage partnerships that could reduce their economic value.
Management said the COVID-19 pandemic could affect clinical studies, regulatory and corporate development activities, and future fundraising; the impact could not be reliably estimated. The filing reported no material change to previously disclosed risk factors, no legal proceedings, and effective disclosure controls as of June 30, 2020.
The 6% convertible exchangeable preferred stock carries a 6% cumulative dividend; accrued and unpaid dividends were approximately $50,000 at June 30. A quarterly dividend of $0.15 per share was declared June 25 and paid August 1, 2020. The company also reported substantial foreign-currency translation and intercompany-loan movements in other comprehensive loss; these are distinct from net loss.
Important facts for investors to verify
- Confirm the registrant identity: the filing text names Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Assess the assumptions supporting management’s cash runway estimate through the end of 2022, including clinical spending, tax-credit receipts and financing needs.
- Review clinical progress and timelines for fadraciclib, sapacitabine, seliciclib and CYC140, including possible COVID-19 disruption.
- Distinguish recurring operating performance from the $835,000 first-half legacy royalty income and assess the uncertain timing of further royalties.
- Evaluate dilution from the financing, outstanding warrants, options, restricted stock units and preferred stock; verify share counts and per-share comparisons in light of the reverse split.